Brief: MediciNova Announces Data From Phase 1b/2a Clinical Trial Of MN-166 In Glioblastoma Patients
03/06/2024 11:23
June 3 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA ANNOUNCES DATA FROM PHASE 1B/2A CLINICAL TRIAL
OF
MN-166 (IBUDILAST) IN GLIOBLASTOMA PATIENTS AT THE AMERICAN
SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2024
* MEDICINOVA INC: COMBINATION OF TEMOZOLOMIDE (TMZ) AND
MN-166 WAS
SAFE AND WELL TOLERATED
Source text for Eikon: ID:nGNX8zTrH0
Further company coverage: MNOV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake